Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics Inc demonstrates a positive growth trajectory, evidenced by the projection of increasing quarterly revenue driven by the deployment of more strategic operational (SO) teams, which can facilitate accelerated adoption and case starts with minimal additional investment. The company's innovative Vivos System has shown significant clinical efficacy, with 93% of patients with severe obstructive sleep apnea achieving a notable milestone of at least a 50% improvement, positioning it favorably in a growing market. Moreover, revenue growth in sleep testing and seminar sponsorship, alongside a robust performance in North America and the Asia Pacific, underscores the company’s potential to capitalize on the rising awareness and healthcare infrastructure advancements in sleep disorder treatment.

Vivos Therapeutics Inc. experienced a year-over-year revenue decline of 9% in the first half of 2025, primarily driven by its transition to a new sleep center operational model, with Q2 revenues reported at $3.8 million, falling short of expectations. Gross margins also deteriorated to 55% in Q2 2025, influenced by discounting practices and changes in the product mix, raising concerns about the company's financial health and profitability. Additionally, persistent risks such as underwhelming sales growth, capital acquisition challenges, and competitive pressures further contribute to the negative outlook for Vivos Therapeutics's stock.